Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts less than Nifty Microcap 250 and 5.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Windlas Biotech reported FY25 consolidated revenue from operations of Rs. 759.88 crore, up about 20.4% from Rs. 630.96 crore in FY24. Net profit for the year rose modestly to Rs. 60.99 crore vs Rs. 58.19 crore last year (about 4.8% growth), with margins roughly flat as depreciation and employee costs rose sharply. Q4 FY25 revenue was Rs. 202.71 crore vs Rs. 171.29 crore in Q4 FY24. Basic EPS for FY25 stood at Rs. 29.19. The board recommended a dividend of Rs. 5.80 per share (116% on face value of Rs. 5) and approved 'Windlas Plan 2025', an ESOP/sweat equity plan subject to shareholder approval. Statutory auditor SS Kothari Mehta & Co LLP issued an unmodified (clean) opinion on the results. The joint venture USpharma Windlas LLC ceased to exist from July 12, 2024.
Strong top-line growth of over 20% is positive, but the muted bottom-line growth suggests cost pressures, particularly higher depreciation from capacity expansion. The healthy dividend and clean audit opinion are shareholder-friendly, while the new ESOP plan may lead to some dilution if approved.